10 results
To provide clinical management and, if required, treatment to subjects who at their concluding HPV-015 study visit displayed normal cervical cytology but tested positive for oncogenic HPV infection or who were pregnant at their concluding visit of…
* To demonstrate efficacy of the candidate vaccine in the prevention of (1) persistent infection (6-month definition) with HPV-16 or HPV-18 (by polymerase chain reaction [PCR]) and/or (2) histopathologically-confirmed CIN1+ associated with HPV-16 or…
Determining the prevalence of testicular microlithiasis in Down syndrome.
1. To prevent multiple pregnancies and the concomittant neonatal mortality and morbidity while retaining acceptable delivery rates in couples with unexplained subfertility or mild male subfertility and poor fertility prospects. 2. To assess the…
Does the installation hyaluronic acid (hyalobarier ® Gel Endo), in patients with M. Asherman reduces or prevents the incidence and severity (ESGE score/classification) of spontaneous recurrence of adhesion better then the IUD without Cu or hormones…
The primary objective of this study is to assess the effectiveness of myo-inositol supplementation to prevent pregnancy complications in women with PCOS. Secondary objectives are to evaluate the impact of supplementation on maternal (mental) and…
Overall we aim for a more effective treatment of provoked vulvodynia with less relapse, taking into account the patients autonomy as an important key to long term cure. Primary outcome: Decrease of pain during (attempt to) penetration, measured by a…
To evaluate RRS with delayed RRO as an alternative for RRSO in BRCA1/2 gene germline mutation carriers. We hypothesize that RRS with delayed RRO leads to an equal ovarian cancer incidence when compared to RRSO.
To evaluate RRS after childbearing with delayed RRO as an alternative for RRSO in BRCA1/2 gene germline mutation carriers. We hypothesize that delay of menopause leads to an improvement of quality of life and sexual functioning, and a decrease in…
To evaluate the long-term effects of GH-therapy on metabolic profile and risk factors for cardiovascular diseases in adults (aged 25-35 years) born SGA and compare this with non-treated adults born SGA and with adults born AGA.